Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000487843 | SCV000109774 | uncertain significance | not provided | 2012-12-12 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000487843 | SCV000575421 | uncertain significance | not provided | 2016-09-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000805387 | SCV000945341 | uncertain significance | Aspartylglucosaminuria | 2022-02-25 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 180 of the AGA protein (p.Gly180Arg). This variant is present in population databases (rs373865451, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with AGA-related conditions. ClinVar contains an entry for this variant (Variation ID: 92309). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV000805387 | SCV001461149 | uncertain significance | Aspartylglucosaminuria | 2020-04-16 | no assertion criteria provided | clinical testing |